Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750398 · ClinicalTrials.gov registry record · Phase 2
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01750398 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 33 participants.
The verdict
NCT01750398, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy.
Interventions
- DRUG Goserelin
- DRUG Testosterone cypionate
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750398
The ClinicalTrials.gov registry entry for NCT01750398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Goserelin is the first listed.
NCT01750398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01750398 about?
NCT01750398 is a clinical study titled "Bipolar Androgen-based Therapy for Prostate Cancer (BAT)". The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes a...
What is the current status of trial NCT01750398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2013-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01750398?
The interventions under investigation include: Goserelin (DRUG), Testosterone cypionate (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT01750398?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.